Kamada (KMDA) Liabilities and Shareholders Equity (2012 - 2026)
Kamada's Liabilities and Shareholders Equity was $383.16 million in the quarter ended Jun 30, 2026, up 4.1% from $368.17 million a year earlier and unchanged from the prior quarter.
Powered by 
Analysis
Kamada (KMDA) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
As of Dec 31, 2025, Liabilities and Shareholders Equity at Kamada came in at $378.71 million, up 1.7% from the prior year.
- Liabilities and Shareholders Equity has now increased for nine consecutive years, with a five-year compound annual growth rate of 12.4% (years ended Dec 2020 to Dec 2025).
- In earlier years, Liabilities and Shareholders Equity was $372.26 million in the year ended Dec 31, 2024 (+4.9%), $354.91 million in the year ended Dec 31, 2023 (+10.1%), $322.38 million in the year ended Dec 31, 2022 (+1.2%) and $318.67 million in the year ended Dec 31, 2021 (+51.3%).
- The figure for the quarter ended Jun 30, 2026 marks the highest quarterly Liabilities and Shareholders Equity in data going back to the quarter ended Jun 30, 2012.
- Compared with a year earlier, Liabilities and Shareholders Equity has increased for 29 straight quarters, with growth averaging 4.8% over the last eight quarters.
- Across the past five years, year-over-year growth in Liabilities and Shareholders Equity ran from 1.2% in the quarter ended Dec 31, 2022 to 51.3% in the quarter ended Dec 31, 2021.
- Per Business Quant data, KMDA's Liabilities and Shareholders Equity in the three quarters before the quarter ended Jun 30, 2026 was $383.02 million (quarter ended Mar 31, 2026), $378.71 million (quarter ended Dec 31, 2025) and $377.21 million (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,261.99 Bn | 1,235.61 Bn | 20.46 Bn | 148.07 Bn |
| 2 | Johnson & Johnson | 678.93 Bn | 598.79 Bn | 17.30 Bn | 197.43 Bn |
| 3 | AbbVie | 518.29 Bn | 486.30 Bn | 13.12 Bn | 147.68 Bn |
| 4 | Merck | 365.98 Bn | 328.92 Bn | 13.19 Bn | 132.77 Bn |
| 5 | Novartis Ag | 316.85 Bn | 290.09 Bn | - | - |
| 6 | Astrazeneca | 293.40 Bn | 267.29 Bn | 13.26 Bn | 119.92 Bn |
| 7 | Amgen | 251.78 Bn | 203.43 Bn | 7.58 Bn | 96.05 Bn |
| 8 | Gilead Sciences | 210.61 Bn | 185.71 Bn | 6.73 Bn | 51.41 Bn |
| 9 | Pfizer | 166.87 Bn | 114.23 Bn | 12.56 Bn | 205.00 Bn |
| 10 | Kamada | 441.57 Mn | 150.63 Mn | 22.47 Mn | 383.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 383.16 Mn |
| Mar 31, 2026 | 383.02 Mn |
| Dec 31, 2025 | 378.71 Mn |
| Sep 30, 2025 | 377.21 Mn |
| Jun 30, 2025 | 368.17 Mn |
| Mar 31, 2025 | 375.11 Mn |
| Dec 31, 2024 | 372.26 Mn |
| Sep 30, 2024 | 351.21 Mn |
| Jun 30, 2024 | 351.04 Mn |
| Mar 31, 2024 | 343.17 Mn |
| Dec 31, 2023 | 354.91 Mn |
| Sep 30, 2023 | 337.06 Mn |
| Jun 30, 2023 | 314.39 Mn |
| Mar 31, 2023 | 316,795.00 |
| Dec 31, 2022 | 322.38 Mn |
| Sep 30, 2022 | 319,637.00 |
| Jun 30, 2022 | 304.14 Mn |
| Mar 31, 2022 | 303.10 Mn |
| Dec 31, 2021 | 318.67 Mn |
| Sep 30, 2021 | 216.53 Mn |
API Access
Kamada Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=KMDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "KMDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=KMDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();